Search company, investor...



Merger | Merged

About Biocorp

Biocorp is a producer of microbiological media and a distributor of diagnostics and reagents for microbiology and molecular biology. On November 28, 2016, Biocorp merged with Biomaxima. The terms of the transaction were not disclosed.

Headquarters Location


Missing: Biocorp's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Biocorp's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Biocorp News

Novo Nordisk begins talks to acquire controlling stake in Biocorp

Jun 6, 2023

The proposed deal values Biocorp at around €154m. Biocorp offers a Bluetooth-enabled smart add-on device for pen injectors. Danish company Novo Nordisk has begun exclusive talks with Bio Jag to purchase a controlling stake in French medical devices maker Biocorp. The company seeks to purchase Bio Jag’s 45.3% stake and 62.2% of its theoretical voting rights in Biocorp for €35 ($37) per share. Recommended Reports The proposed deal values Biocorp at roughly €154m ($164m). Certain minority shareholders, including Nyenburgh, Greenstock and Vatel Capital, also agreed to transfer their shares to Novo Nordisk. These shareholders together hold around 19% of the share capital and 13.07% of the theoretical voting rights. Biocorp CEO Eric Dessertenn said: “This potential combination rewards our efforts, begun five years ago, to digitalise the treatment and monitoring of chronic patients, with the constant aim of easing their daily lives.” Biocorp has expertise in the design, development and production of advanced medical devices and delivery systems, including a Bluetooth-enabled smart add-on device called Mallya for pen injectors. Novo Nordisk started its collaboration with Biocorp in 2021. The collaboration is focused on developing and commercialising a Mallya add-on device for the Novo Nordisk FlexTouch pen to treat diabetes individuals. The partnership has been broadened to include the creation of the Mallya device versions for various therapy areas. Novo Nordisk devices and delivery solutions senior vice-president Marianne Ølholm said: “We have enjoyed a fruitful collaboration with Bioxcorp over the past couple of years, and we hope to be able to welcome the company and its highly skilled workers into Novo Nordisk to complement our in-house efforts within connected delivery solutions and accelerate our ambitions within devices and delivery solutions.” Share this article

Biocorp Frequently Asked Questions (FAQ)

  • What is Biocorp's latest funding round?

    Biocorp's latest funding round is Merger.

  • Who are the investors of Biocorp?

    Investors of Biocorp include Biomaxima.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.